B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PRKD1

MOLECULAR TARGET

protein kinase D1

UniProt: Q15139NCBI Gene: 558723 compounds

PRKD1 (protein kinase D1) is targeted by 23 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PRKD1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1gefitinib5.67290
2alvocidib4.5291
3bi 25364.0154
4brigatinib3.8144
5neratinib3.6638
6nintedanib3.6136
7bms 3870323.4731
8tae 6843.4330
9jnj 77066213.0921
10at 92833.0921
11lestaurtinib3.0420
12pf 037583093.0019
13go 69762.8917
14k 252a2.8316
15bms 3455412.7114
16kw 24492.6413
17gsk 6906932.6413
18ast 4872.5612
19hypothemycin2.4010
20su 0148132.208
21sra 7371.956
22Crizotinib0.691
23hydroxyfasudil [Supplementary Concept]0.691

About PRKD1 as a Drug Target

PRKD1 (protein kinase D1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 23 compounds with documented PRKD1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PRKD1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.